These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27655663)

  • 1. Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo.
    Torres A; Kozak J; Korolczuk A; Rycak D; Wdowiak P; Maciejewski R; Torres K
    Oncotarget; 2016 Nov; 7(45):73651-73663. PubMed ID: 27655663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo activity of miR-92a-Locked Nucleic Acid (LNA)-Inhibitor against endometrial cancer.
    Torres A; Kozak J; Korolczuk A; Wdowiak P; Domańska-Glonek E; Maciejewski R; Torres K
    BMC Cancer; 2016 Oct; 16(1):822. PubMed ID: 27782822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach.
    Nedaeinia R; Sharifi M; Avan A; Kazemi M; Rafiee L; Ghayour-Mobarhan M; Salehi R
    Cancer Gene Ther; 2016 Aug; 23(8):246-53. PubMed ID: 27364574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α.
    Chen S; Sun KX; Liu BL; Zong ZH; Zhao Y
    Mol Cancer; 2016 Feb; 15():11. PubMed ID: 26832151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.
    Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P
    PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells.
    Zhuo Z; Yu H
    Oncotarget; 2017 Apr; 8(17):28042-28051. PubMed ID: 28427207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1.
    Xu YY; Wu HJ; Ma HD; Xu LP; Huo Y; Yin LR
    FEBS J; 2013 Aug; 280(16):3768-79. PubMed ID: 23731275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer.
    He Z; Xu H; Meng Y; Kuang Y
    Biomed Pharmacother; 2017 Apr; 88():902-910. PubMed ID: 28178620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.
    Monoe Y; Jingushi K; Kawase A; Hirono T; Hirose R; Nakatsuji Y; Kitae K; Ueda Y; Hase H; Abe Y; Adachi J; Tomonaga T; Tsujikawa K
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA miR-302 inhibits the tumorigenicity of endometrial cancer cells by suppression of Cyclin D1 and CDK1.
    Yan GJ; Yu F; Wang B; Zhou HJ; Ge QY; Su J; Hu YL; Sun HX; Ding LJ
    Cancer Lett; 2014 Apr; 345(1):39-47. PubMed ID: 24333727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-152 inhibits proliferation of human endometrial cancer cells via inducing G2/M phase arrest by suppressing CDC25B expression.
    Xie D; Liang Y; Su Y; An Y; Qu P
    Biomed Pharmacother; 2018 Mar; 99():299-305. PubMed ID: 29353204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.
    Nishimura T; Nakamura K; Yamashita S; Ikeda S; Kigure K; Minegishi T
    BMC Cancer; 2015 Dec; 15():957. PubMed ID: 26673416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma.
    Park YA; Lee JW; Choi JJ; Jeon HK; Cho Y; Choi C; Kim TJ; Lee NW; Kim BG; Bae DS
    Gynecol Oncol; 2012 Jan; 124(1):125-33. PubMed ID: 22015043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A.
    Ye W; Xue J; Zhang Q; Li F; Zhang W; Chen H; Huang Y; Zheng F
    Oncol Rep; 2014 Sep; 32(3):1193-9. PubMed ID: 24993091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of ghrelin receptor expression inhibits endometrial cancer cell growth in vitro and in vivo.
    Fung JN; Jeffery PL; Lee JD; Seim I; Roche D; Obermair A; Chopin LK; Chen C
    Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E305-13. PubMed ID: 23736537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of miR-1202 and miR-196a in human endometrial cancer based on high throughout gene screening analysis.
    Chen H; Fan Y; Xu W; Chen J; Meng Y; Fang D; Wang J
    Oncol Rep; 2017 Jun; 37(6):3493-3501. PubMed ID: 28440476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progesterone-Induced miR-152 Inhibits the Proliferation of Endometrial Epithelial Cells by Downregulating WNT-1.
    Nie L; Zhao YB; Pan JL; Lei Y; Liu M; Long Y; Zhang JH; Hu Y; Xu MQ; Yuan DZ; Yue LM
    Reprod Sci; 2017 Oct; 24(10):1444-1453. PubMed ID: 28122483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-10b Inhibits Apoptosis and Promotes Proliferation and Invasion of Endometrial Cancer Cells via Targeting HOXB3.
    Chen H; Fan Y; Xu W; Chen J; Xu C; Wei X; Fang D; Feng Y
    Cancer Biother Radiopharm; 2016 Aug; 31(6):225-31. PubMed ID: 27447302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC).
    Liu BL; Sun KX; Zong ZH; Chen S; Zhao Y
    Oncotarget; 2016 Feb; 7(6):6649-64. PubMed ID: 26673619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7.
    Li Q; Qiu XM; Li QH; Wang XY; Li L; Xu M; Dong M; Xiao YB
    Oncol Rep; 2015 May; 33(5):2354-60. PubMed ID: 25708247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.